drugset
Drugs / RG6029
last change Jun 2017 re-read 3 minutes ago

RG6029

also known as GDC-0310

targets SCN9A via inhibition

Investigated by
Genentech, Inc.

Trials 1

today NCT02742779 · Ph 1
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02742779 Sep 2015 → Jun 2017 — Genentech, Inc. Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2015-10-22 Xenon Pharmaceuticals Inc. Xenon Announces Its Partner Genentech Has Advanced GDC-0310, a Second Nav1.7 Inhibitor for Pain, Into Clinical Development xenon-pharma.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as RG6029 ChEMBL registry synonym — accepted as the source's own label CHEMBL3707380 ↗
Known as GDC-0310 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02742779 ↗
Action Inhibit “Sodium channel protein type IX alpha subunit blocker” CHEMBL3707380 ↗
Route Oral “GDC-0310 orally in fasted or fed state.” NCT02742779 ↗
Target SCN9A “Sodium channel protein type IX alpha subunit blocker” CHEMBL3707380 ↗